Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
复制标题
新型抗分枝杆菌药物的开发前景，特别是新型苯并恶嗪诺福霉素，KRM-1648。
DOI：
--
复制
发表时间：
2000
影响因子：
3.2
通讯作者：
H. Tomioka
中科院分区：
文献类型：
--
作者：
H. Tomioka
在这篇文章中，我全面回顾了新型抗分枝杆菌药物的开发现状，特别是利福霉素衍生物（利福布丁、利福喷丁和新型苯并恶嗪利福霉素KRM-1648），氟喹诺酮类药物（环丙沙星，氧氟沙星，司帕沙星，左氧氟沙星，加替沙星，西他沙星，莫西沙星等），新的大环内酯类药物（克拉霉素、阿奇霉素、罗红霉素）等。在这篇综述中，我主要描述了这些药物针对结核分枝杆菌和非典型分枝杆菌，特别是鸟分枝杆菌复合体的体外和体内活性。此外，还简要提及了这些药物在临床治疗分枝杆菌感染病例中的治疗效果。
In this article, I have thoroughly reviewed the status of development of new antimycobacterial drugs, in particular, rifamycin derivatives (rifabutin, rifapentine, and a new benzoxazinorifamycin, KRM-1648), fluoroquinolones (ciprofloxacin, ofloxacin, sparfloxacin, levofloxacin, gatifloxacin, sitafloxacin, moxifloxacin, and others), new macrolides (clarithromycin, azithromycin, roxithromycin), and others. In this review, I have mainly described the in vitro and in vivo activities of these drugs against Mycobacterium tuberculosis and atypical mycobacteria, especially Mycobacterium avium complex. In addition, therapeutic efficacy of these drugs in cases of clinical treatment of mycobacterial infections have also been briefly mentioned.